The therapeutic approach includes first targeting the receptors of vascular endothelial growth factor (VEGFR) with immunotherapy (bevacizumab) or administration of protein kinase inhibitors (sunitinib) approved for advanced stages of cancer [46]. This evidence concerns the gene KDR and cancer.